Haleos Labs Limited (HALEOSLABS) Financial History

Name: Haleos Labs Limited (HALEOSLABS) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-09-20

Haleos Labs Limited (HALEOSLABS) operates in the Biotechnology industry and is headquartered in Hyderabad, India with about 611 employees. Its market capitalization is roughly ₹5 billion. In the fiscal year ended 2026-03-31, HALEOSLABS reported ₹3.2B in revenue and ₹173M in net income.

Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India.

Interactive charts & full statements →

HALEOSLABS Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Total Revenue	₹3.2B	₹3.4B	₹3.0B	₹3.1B
Gross Profit	₹1.1B	₹1.2B	₹908M	₹846M
Operating Income (EBIT)	₹302M	₹301M	₹163M	₹180M
Net Income	₹173M	₹201M	₹91M	₹115M

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

HALEOSLABS Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total Revenue	₹729M	₹751M	₹948M	₹814M	₹825M
Gross Profit	₹308M	₹292M	₹336M	₹330M	₹309M
Operating Income (EBIT)	₹49M	₹3M	₹101M	₹97M	₹79M
Net Income	₹26M	₹4M	₹66M	₹61M	₹42M

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

HALEOSLABS Free Cash Flow History

Cash flow	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Dividends Paid	(₹4M)	(₹4M)	(₹4M)	(₹4M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

HALEOSLABS Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹4.5B	₹3.9B	₹3.9B	₹3.9B	—
Total Liabilities	₹2.2B	₹1.8B	₹2.0B	₹2.1B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive HALEOSLABS viewer.

Other Companies in Biotechnology

2256 · Abbisko Cayman Limited — HK$6 billion
BANB · Bachem Holding AG — CHF 6 billion
0775 · CK Life Sciences Int'l., (Holdings) Inc. — HK$5 billion
2183 · Linical Co., Ltd. — JPY 5 billion
1167 · Jacobio Pharmaceuticals Group Co., Ltd. — HK$4 billion
2342 · Transgenic Group Inc. — JPY 4 billion
1477 · Ocumension Therapeutics — HK$4 billion
2617 · TransThera Sciences (Nanjing), Inc. — HK$4 billion

← HALDYNGL All “H” companies HALO →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.